What is the maximum tolerated dose of ruxolitinib?

The maximum tolerated dose (MTD) of ruxolitinib (JAKAVI) depends on the patient's specific circumstances, including indication, individual tolerability, and renal or hepatic function status. In general, when treating myelofibrosis (MF), the recommended starting dose is 15mg or 20mg twice daily, depending on platelet count. In the treatment of polycythemia vera (PV), the recommended dose is usually 10 mg twice daily. For acute graft-versus-host disease (aGVHD), the dose may be adjusted.

In clinical studies, the maximum tolerated dose of ruxolitinib is generally considered to be 25 mg twice daily. However, dose escalation is limited by patient blood counts and management of side effects. Excessive dosage may lead to hematological toxicities such as anemia, thrombocytopenia, and neutropenia, so blood routine monitoring needs to be closely monitored and the dosage adjusted or treatment suspended if necessary.

The maximum tolerated dose may need to be reduced in patients with impaired renal or hepatic function. In patients with moderate or severe hepatic impairment, the initial dose is usually reduced to 5 mg or 10 mg twice daily and adjusted to tolerability. In patients with severe renal impairment (creatinine clearance <30 mL/min), dose reduction and close monitoring for adverse reactions are recommended.

In general, the tolerated dose of ruxolitinib varies depending on individual patient conditions, and the maximum tolerated dose usually does not exceed 25 mg twice daily. Doctors will adjust the dose based on the patient's blood picture changes, drug response and clinical manifestations to ensure that the drug is effective while minimizing side effects. Patients should regularly review blood routine during use, and seek medical advice promptly to adjust the treatment plan if severe side effects occur.

xa0

Reference materials:https://www.jakavi.com/